세계의 다한증 치료 시장(2022-2028년) : 치료법(Botulinum toxic A, lontophoresis), 유형(원발성 국소성 다한증, 2차성 전신성 다한증), 최종사용자(병원, 외래)별 규모, 점유율, 성장 분석, 예측
Global Hyperhidrosis Treatment Market Size, Share, Growth Analysis, By Treatment(Botulinum toxic A, lontophoresis), By Type(Primary focal, secondary generalized), By End User(Hospitals, ambulatory) - Industry Forecast 2022-2028
세계 다한증 치료 시장 규모는 2021년 12억 달러에서 예측 기간 동안 6.2%의 CAGR로 추이하고 2028년에는 20억 달러 규모로 성장할 것으로 예측됩니다.
2차성 다한증 질환의 발생률의 상승이나 참가 기업에 의한 R&D 투자의 증가가 이 시장의 성장을 뒷받침하고 있는 주된 이유입니다.
본 보고서에서는 세계의 다한증 치료 시장을 조사하여 시장 개요, 시장에 대한 각종 영향요인 분석, 기술 및 혁신 동향, 시장 규모 추이·예측, 각종 구분, 지역별 분석, 경쟁 정세, 주요 기업 프로필 등을 정리했습니다.
Global hyperhidrosis treatment market was valued at USD 1.2 billion in 2021 and is expected to reach USD 2 billion by 2028. The market is anticipated to grow at a CAGR of 6.2% during the forecast period (2022-2028).
The first line of defence in the battle against hyperhidrosis is antiperspirants and topical drugs. Hyperhidrosis, however, has no known treatment at this time. In recent years, there has been a lot of activity in the development of new products and technology. Businesses have invested in this industry as a result of the public's growing awareness of potential therapies and patients' need for cutting-edge techniques.
The rising incidence of secondary hyperhidrosis diseases and market participants increasing their R&D investment are the main reasons fueling the market expansion for hyperhidrosis therapeutics. According to a study by Jared Brackenrich that was published in the National Library of Medicine in October 2021, this ailment is thought to occur quite frequently in the United States, with an estimated 3% incidence. Hyperhidrosis may impair social, psychological, emotional, and vocational functioning. Thus, it is predicted that the increasing prevalence of hyperhidrosis will increase the need for treatment and, as a result, accelerate market expansion.
A possible therapy pipeline for the ailment could have an effect on market growth in addition to favourable reimbursement policies, higher rates of anxiety and depression, and increased public awareness of hyperhidrosis. For instance, Brickell Biotech Inc. released encouraging topline findings from the Phase 3 pivotal Cardigan I and Cardigan II investigations in October 2021. These studies assessed the effectiveness of 15% sofpironium bromide gel applied topically once daily in patients with primary axillary hyperhidrosis.
Top-down and bottom-up approaches were used to estimate and validate the size of Asia Pacific Hyperhidrosis treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Segments covered in this report
The market is divided into segments based on end user, area, kind of hyperhidrosis, and type of treatment. The market is segmented by type of treatment, including non-surgical microwave energy destruction of sweat glands, lontophoresis, surgical treatment, tropical treatment, and botulinum toxic A. There are two types of hyperhidrosis: primary focused and secondary widespread. It is separated into hospitals, ambulatory, surgical centres, and other facilities according on the end user (dermatology clinics & cosmetic centers). It is separated into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa based on region.
The effects of hyperhidrosis therapy based on radiofrequency microneedling on patients with the ailment are being studied by medical professionals. Stakeholders are attempting to discover whether fractional microneedle radiofrequency treatment offers long-term benefits, particularly for patients with primary axillary hyperhidrosis. These studies' analysis of the hyperhidrosis disease severity scale (HDSS) revealed that patients' conditions dramatically improved after taking medication.
Another hyperhidrosis treatment that is gaining popularity among patients is tap water iontophoresis, which involves transporting an ionised material through the skin using a direct electric current. In numerous treatment trials, patients with plantar and palmar hyperhidrosis demonstrated significant improvements. Patients are able to live better lifestyles and perspire significantly less as a result of these positive effects.
The most recent market-related R&D projects are gaining popularity on a global basis. For instance, Brickell Biotech Inc. released upbeat topline results from the Phase 3 pivotal Cardigan I and II studies, which examined the efficacy of 15% sofpironium bromide gel applied topically once daily in patients with primary axillary hyperhidrosis. This quickens market growth.
Particularly botulinum toxin injections have a lot of drawbacks, such as its transient efficacy in people who grow less tolerant to the dosage as they become accustomed to it. Another issue harming the market for hyperhidrosis treatments is the financial load and psychological distress that patients endure as a result of many medical insurance companies not covering hyperhidrosis treatment.
OnabotulinumtoxinA can be used to treat excessive sweating in the armpits, hands, feet, head, face, and other relatively small body areas, according to an article that was published in the International Hyperhidrosis Society in October 2020. (such under the breasts). When used to treat excessive sweating beneath the arms, Botox has been shown to reduce sweating by 82-87%. The effects of treatment often begin to apparent two to four days after the procedure and reach their peak two weeks later. Despite typically lasting 4 to 12 months, dryness can continue up to 14 months, according to some research.
Several studies have shown how effective it is at reducing anxiety. A study from 2021 that was published in the journal Scientific Reports found that persons who had Botox injections at four different locations experienced significantly less anxiety than those who received other treatments for the same conditions. In Botox patients, anxiety was seen to be reduced by 22-72%.